Of the CD117 monoclonal antibodies, JSP191 has advanced the furthest, with phase I/II in-human clinical trials investigating the addition of JSP191 in conditioning regimens for AML and MDS [46], severe combined immunodeficiency (SCID) [47] and Fanconi anaemia [48]. This evidence concerns the gene KIT and acute myeloid leukemia.